qCT Lung (v1.0)
Qure.Ai Technologies Pvt. , Ltd. · Decision date Sep 14, 2026
What did the FDA decide?
FDA's records show a substantially equivalent (SESE) decision dated September 14, 2026 for qCT Lung (v1.0), submitted by Qure.Ai Technologies Pvt., Ltd. under K261517. The device is a Class II radiological computer-assisted detection and diagnosis software under 21 CFR 892.2090, product code QDQ, in the radiology specialty. The public database lists the application as a traditional 510(k) received May 7, 2026, with a predetermined change control plan authorized. SESE means clearance to market, not PMA approval.
The 510(k) summary describes an AI-based tool that processes non-contrast DICOM CT images to assist radiologists and pulmonologists in detecting, characterizing and quantifying pulmonary nodules, deployable on cloud or on-premises servers. The stated indication covers CT scans from a lung cancer screening population, with nodule size 4–30 mm, and describes the software as adjunctive rather than a replacement for physician review. The summary names Lunit INSIGHT DBT v1.1 (K242652) as predicate and ClearRead CT and Philips LNA as reference devices. Performance data and the content of the authorized change control plan are not in the supplied excerpts.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 14, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261517
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Qure.Ai Technologies Pvt. , Ltd.
- Product code
- QDQ
- Decision code
- SESE
- Decision date
- Sep 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer.
- Applicant
- Qure.Ai Technologies Pvt. , Ltd.
- Product code
- QDQ
- FDA device class
- 2
FDA decision timeline
K261517 received
Application receipt date recorded by FDA.
K261517 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QDQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CadAI-B DxK263749 | BeamWorks, Inc. | 510(k) clearance | Nov 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Qure.Ai Technologies Pvt. , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Mumbai
Sources and methodology
- Original FDA record: K261517
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records